Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).

Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).

Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).

Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).

Abstract: An odor absorbing system includes a lower body covering article of clothing configured to be worn by a person. The lower body covering article of clothing includes a base layer comprising a crotch section and leg sections, each of which are connected to the crotch section. The crotch and leg sections are respectively configured to substantially cover the crotch and legs of the person wearing the article of clothing.

Abstract: An odor absorbing system includes a head covering article of clothing configured to be worn by a person. The head covering article of clothing includes a base layer comprising a cap section configured to substantially cover a head of the person wearing the article of clothing. An odor absorbing insert is removable attachable to the article of clothing.

Abstract: An odor absorbing system for use by a person to reduce odor emanation from the person into an environment surrounding the person. The system includes a container having a substantially airtight interior chamber and an odor absorbing insert stored in the interior chamber. The insert includes a layer of breathable material and an odor absorbing agent on the layer of breathable material. The insert is configured for removable attachment to the article of clothing adjacent the vent.

Abstract: An odor absorbing system for use by a person to reduce odor emanation from the person into an environment surrounding the person includes an article of clothing that is configured to be worn by the person and an odor absorbing insert removably attached to the article of clothing. The article of clothing includes a base layer that is adapted to substantially surround a portion of the person wearing the article of clothing. The base layer includes a vent. The odor absorbing insert is configured to cover the vent and includes a layer of breathable material and an odor absorbing agent on the layer of breathable material.

Abstract: Concentrated solutions of carotenoids in essential oils and cosmetic oils for use in foods, beverages, and personal care products. The concentrated solutions comprise between about 0.8 weight % and about 8 weight % carotenoid in the oil, or between about 15 times and about 100 times the maximum concentration reported in the prior art. The concentrated solutions are particularly suited for adding carotenoids to foods, beverages, and personal care products. An antioxidant may be added to help in preventing oxidation of the carotenoid.

Abstract: An example embodiment is directed to use in a facility benefiting from the distribution of audio throughout different facility zones (“audio zones”), with each audio zone receiving an audio signal from a remotely-located audio distribution controller. For controlling audio at a user-controlled speaker load located in one of the audio zones, a circuit arrangement includes isolation circuit, speaker load circuit, user-input device and an audio control unit. The isolation circuit generate a transformed audio signal by provide an impedance-matched termination and by permitting one of a number of impedance-matching circuits to be set wherein each impedance-matching circuit provides a different amount of electrical power to the speaker load. The speaker load circuit delivers, in response to the transformed audio signal, audible signals in the audio zone.

Abstract: Concentrated solutions of carotenoids in essential oils and cosmetic oils for use in foods, beverages, and personal care products. The concentrated solutions comprise between about 0.8 weight % and about 8 weight % carotenoid in the oil, or between about 15 times and about 100 times the maximum concentration reported in the prior art. The concentrated solutions are particularly suited for adding carotenoids to foods, beverages, and personal care products. An antioxidant may be added to help in preventing oxidation of the carotenoid.

Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).

Abstract: A non-linear editing system for home audio and video applications includes a compression/decompression engine, a high capacity storage device and a media editor that provides point and click audio and video editing functionality, including recording, playback and special effects, such as real time gamma correction, color effects, 2D effects and real time fades, using a time-line system. The media editor includes a configurable Shaped Cut, Relocate, Alpha and Mixer (SCRAM) engine to mix, shape cut and relocate portions of images. In addition, the SCRAM engine supports pixel weighting to enable drawing and movement of transparent objects for video overlay operations. The compression/decompression engine includes electronic circuitry designed to implement high speed data compression and decompression using JPEG, MPEG or wavelet techniques.

Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).

Abstract: Novel human monoclonal antibodies, and their corresponding nucleic acid sequences having high affinity for the human RSV-F protein are provided.

Abstract: A method of detecting RSV (Respiratory Syncytial Virus) in an analyte using high affinity human monoclonal antibodies is provided.

Abstract: A method of obtaining high affinity human monoclonal antibodies having a Kd of .ltoreq.2.times.10.sup.-9 molar in SCID mice is provided.

Abstract: A method of treating or preventing RSV infection by the administration of high affinity human monoclonal antibodies having a Kd of about 2.times.10.sup.-9 to 10.sup.-10 molar is provided.

Abstract: A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein about 2.times.10.sup.-9 to 10.sup.-10 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.

Abstract: A pet feeder provides a food dish surrounded by a water moat which flows in common with an open watering portion of the pet feeder. A separate portion of the feeder provides a water storage bottle held in the inverted orientation so as to replenish water in the feeder automatically. A float controlled water inlet may also be used to maintain water level.